VTVT News and Press, vTv Therapeutics Inc. From 03/18/21

HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechan...

HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H...

5 Penny Stocks To Watch This Week With the approval of a new vaccine and a bullish response from investors, penny stocks are showing higher volume across the board. While heightened volume may not seem like a big deal, it indicates several factors about individual security. For one, hig...

As February comes to a close, we are seeing more volatility than ever among both blue chip and penny stocks . To understand why let’s take a look at some of the overall factors that are impacting the stock market today. First, the $1.9 trillion stimulus package has sparked lo...

vTv Therapeutics (VTVT): Q4 GAAP EPS of $0.02 beats by $0.08.Revenue of $6.4M beats by $4.75M.Press Release For further details see: vTv Therapeutics EPS beats by $0.08, beats on revenue

Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal HIGH POINT, N.C...

vTv Therapeutics ([[VTVT]] -8.4%) announces that the results from the JDRF-supported SimpliciT-1 Study were published in the American Diabetes Association’s Diabetes Care journal, where treatment with 800mg of TTP399 showed statistically significant reductions in HbA1c blood sugar leve...

HIGH POINT, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) and inflammatory diseases, today announced that the results from th...

vTv Therapeutics (VTVT) announces the initiation of a phase 1 multiple ascending dose study evaluating an orally administered phosphodiesterase type 4 ((PDE4)) inhibitor, HPP737, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy adult voluntee...

Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara Biopharma, has initiated a phase 2 study in COPD in China HIGH POINT, N.C....